Fig. 4.
Multivariable sensitivity analysis of the differences in total annual health plan costs per PASI 75 among a biologic-naïve and b biologic-experienced patients treated with ustekinumab vs. brodalumab. PASI Psoriasis Area Severity Index
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.